Source: Virtual Congress 2021 – Inhaled treatments for COPD: real-world data



Rating:

Share or cite this content

Citations should be made in the following way:
C. Rhee (Seoul, Republic of Korea), Y. Kim (Chuncheon, Republic of Korea), Y. Hwang (Anyang, Republic of Korea), K. Yoo (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), K. Jung (Seoul, Republic of Korea), Y. Park (Seoul, Republic of Korea). Comparing pneumonia incidence in COPD patients treated with or without inhaled corticosteroid. 2410

Member's Comments

No comment yet.

Related content which might interest you: Assessing the incidence pattern of pneumonia among COPD patients with or without exposure to inhaled steroids Source: Annual Congress 2007 - Epidemiology of COPD Year: 2007 Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia Source: Eur Respir J 2010; 36: 751-757 Year: 2010 Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia Source: Eur Respir J 2011; 37: 36-41 Year: 2011 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901035; 10.1183/13993003.01035-2019 Year: 2019 Inhaled corticosteroids and pneumonia mortality in COPD patients Source: Eur Respir J, 54 (3) 1901276; 10.1183/13993003.01276-2019 Year: 2019 Impact of inhaled corticosteroid use on outcome in COPD patients hospitalised with pneumonia Source: Annual Congress 2010 - Aetiology and outcomes of infective exacerbations of COPD Year: 2010 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Are COPD patients with pneumonia who are taking inhaled corticosteroids at higher risk of dying? Source: Eur Respir J 2011; 37: 1-3 Year: 2011 Risks of pneumonia in asthmatic patients taking inhaled corticosteroids Source: Annual Congress 2010 - Management of airway disease Year: 2010 Predictors of inhaled corticosteroid therapy in COPD alone compared to COPD with concomitant asthma managed in primary care Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD Source: Annual Congress 2012 - COPD: risk factors, biomarkers and diagnosis Year: 2012 Reduced risk for asthma exacerbations in pediatric patients receiving salmeterol plus inhaled corticosteroids (ICS) vs. ICS alone Source: Eur Respir J 2004; 24: Suppl. 48, 308s Year: 2004 Characteristics of COPD patients treated with inhaled corticosteroid in primary care Source: International Congress 2018 – Biomarkers for evaluating COPD Year: 2018 Out-patient combination therapy with inhaled corticosteroids and bronchodilators is associated with lower in-hospital mortality in pneumonia in patient with COPD Source: International Congress 2016 – Prevalence, prognosis, and risk factors of COPD Year: 2016 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Inhaled corticosteroid related pneumonia in real world among the patients with asthma and COPD Source: International Congress 2017 – Asthma and allergy: from the bench to the bedside Year: 2017 Inhaled corticosteroids and the risk of a first exacerbation in COPD patients Source: Eur Respir J 2004; 23: 692-697 Year: 2004 Inhaled corticosteroid therapy on admission of hospitalized patients with COPD Source: Eur Respir J 2002; 20: Suppl. 38, 243s Year: 2002 Low-dose corticosteroid use and mortality in severe community-acquired pneumonia patients Source: Eur Respir J 2015; 45: 463-472 Year: 2015 Are inhaled corticosteroids increasing the “load” for some patients with COPD? Source: Eur Respir J, 50 (4) 1701848; 10.1183/13993003.01848-2017 Year: 2017